TG Therapeutics, Inc. (TGTX) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate TG Therapeutics, Inc.'s investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
9.62
Strong
WeakModerateStrong
P/B Ratio
6.64
Weak
WeakModerateStrong
Earnings Yield
10.39%
Strong
WeakModerateStrong
Profitability Health
2025Return on Equity
69.01%
Strong
WeakModerateStrong
Operating Margin
20.01%
Strong
WeakModerateStrong
Net Profit Margin
72.56%
Strong
WeakModerateStrong
Growth Indicators
2025Revenue Growth
87.32%
Strong
WeakModerateStrong
Net Income Growth
1812.41%
Strong
WeakModerateStrong
EPS Growth
1837.50%
Strong
WeakModerateStrong
Efficiency & Liquidity
2025Current Ratio
4.10
Strong
WeakModerateStrong
Quick Ratio
3.29
Strong
WeakModerateStrong
Asset Turnover
0.58x
Moderate
WeakModerateStrong
Inventory Turnover
0.80x
Weak
WeakModerateStrong
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
-0.58%
Weak
WeakModerateStrong
EV / Free Cash Flow
-179.45x
Strong
WeakModerateStrong
Net Debt / EBITDA
1.35x
Moderate
WeakModerateStrong
Interest Burden (EBT / EBIT)
0.871
Moderate
WeakModerateStrong
Return on Invested Capital
13.54%
Weak
WeakModerateStrong
Cash Conversion Cycle
246.53 days
Weak
WeakModerateStrong
Fortress screener guardrails
1/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for TGTX.
View Financial Statements